RxDoctor Payments DataLook up a doctor →

James Stevens, MD

Neurology · Fort Wayne, INNPI 1437156239

Payments from drug & device makers

$1,502,862in general payments, 2019–2025

Across 435 payments — averaging $3454.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$899K
  • Genentech, Inc.$383K
  • AbbVie$63K
  • Eisai Inc.$58K
  • AstraZeneca$51K
  • Jazz Pharmaceuticals Inc.$26K
  • plus $23K from 21 others

What the payments were for

  • Consulting fees$1,62932%
  • Speaking & faculty fees$96619%
  • Food & beverage$2,46149%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,502,862 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$859,889
Medicare patients
452
Services billed
82,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam22$579,444
NuplazidPimavanserin Tartrate33$156,432
TecfideraDimethyl Fumarate14$132,228
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$122,971
Teriflunomide36$103,514
Sodium Oxybate11$101,379
AubagioTeriflunomide11$101,352
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5014$73,379
Glatiramer Acetate26$43,461
GlatopaGlatiramer Acetate18$29,109
QuliptaAtogepant23$25,923
NeuproRotigotine18$25,157
XcopriCenobamate15$18,137
Rivastigmine73$15,174
RytaryCarbidopa/Levodopa19$14,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$35$156,43233 claims
BiogenTecfidera$898,902$132,22814 claims
SanofiAubagio$33$101,35211 claims
AbbVieQulipta, Savella$62,628$31,35834 claims
UCB, Inc.Neupro$15$25,15718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.

Other neurology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →